Importance of low-grade albuminuria

Mayo Clinic Proceedings

Volumn 83, Issue 7, 2008, Pages 806-812

  Danziger, John ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DA517 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

ALBUMINURIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COLORIMETRY; DISEASE ASSOCIATION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MICROALBUMINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; URINARY EXCRETION; VASCULAR DISEASE;

EID: 46749140859     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/83.7.806     Document Type: Review

References (94)

1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038-2047.
2. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67(6):2089-2100.
3. US Renal Data System. USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive Kidney Diseases; 2006. http://www.usrds.org/adr_2006.htm. Accessed May 21, 2008.
4. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003;42(5):1050-1065.
5. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-1305.
6. Rahman M, Brown CD, Coresh J, et al; ALLHAT Collaborative Research Group. The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Arch Intern Med. 2004;164(9):969-976.
7. Rahman M, Pressel S, Davis BR, et al; ALLHAT Collaborative Research Group. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med. 2006;144(3):172-180.
8. Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000;36(1):29-34.
9. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352(20):2049-2060.
10. Shlipak MG, Katz R, Sarnak MJ, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006;145(4):237-246.
11. Sarnak MJ, Katz R, Stehman-Breen CO, et al, Cardiovascular Health Study. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med. 2005;142(7):497-505.
12. Schmieder RE, Schrader J, Zidek W, et al. Low-grade albuminuria and cardiovascular risk: what is the evidence? Clin Res Cardiol. 2007 May;96(5):247-257. Epub 2007 Apr 26.
13. Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol. 2007 May;2(3):581-590. Epub 2007 Feb 14.
14. Tojo A, Endou H. Intrarenal handling of proteins in rats using fractional micropuncture technique. Am J Physiol. 1992;263 (4, pt 2):F601-F606.
15. Schaeffer RC Jr, Gratrix ML, Mucha DR, Carbajal JM. The rat glomerular filtration barrier does not show negative charge selectivity. Microcirculation. 2002;9(5):329-342.
16. Russo LM, Sandoval RM, McKee M, et al. The normal kidney filters nephrotic levels of albumin retrieved by proximal tubule cells: retrieval is disrupted in nephrotic states. Kidney Int. 2007 Mar;71(6):504-513. Epub 2007 Jan 17.
17. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia. 1989;32(4):219-226.
18. Ruggenenti P, Remuzzi G. Time to abandon microalbuminuria? Kidney Int. 2006 Oct;70(7):1214-1222. Epub 2006 Jul 26.
19. Pedrinelli R, Dell'Omo G, Di Bello V, Pontremoli R, Mariani M. Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J Hum Hypertens. 2002;16(2):79-89.
20. Pontremoli R, Cheli V, Sofia A, et al. Prevalence of micro- and macroalbuminuria and their relationship with other cardiovascular risk factors in essential hypertension. Nephrol Dial Transplant. 1995;10(suppl 6):6-9.
21. Winocour PH, Harland JO, Millar JP, Laker MF, Alberti KG. Microalbuminuria and associated cardiovascular risk factors in the community. Atherosclerosis. 1992;93(1-2):71-81.
22. Campese VM, Bianchi S, Bigazzi R. Association between hyperlipidemia and microalbuminuria in essential hypertension. Kidney Int Suppl. 1999 Jul;71:S10-S13.
23. Vedovato M, Lepore G, Coracina A, et al. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia. 2004 Feb;47(2):300-303. Epub 2003 Dec 24.
24. Orchard TJ, Chang YF, Ferrell RE, Petro N, Ellis DE. Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int. 2002;62(3):963-970.
25. Mykkänen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the Insulin Resistance Atherosclerosis Study. Diabetes. 1998;47(5):793-800.
26. Pedrinelli R, Dell'Omo G, Di Bello V, et al. Low-grade inflammation and microalbuminuria in hypertension. Arterioscler Thromb Vasc Biol. 2004 Dec;24(12):2414-2419. Epub 2004 Oct 14.
27. Castells I, Salinas I, Rius F, et al. Inducible myocardial ischaemia in asymptomatic type 2 diabetic patients. Diabetes Res Clin Pract. 2000;49(2-3):127-133.
28. Mehrotra R, Budoff M, Christenson P, et al. Determinants of coronary artery calcification in diabetics with and without nephropathy. Kidney Int. 2004;66(5):2022-2031.
29. Mehrotra R, Budoff M, Hokanson JE, Ipp E, Takasu J, Adler S. Progression of coronary artery calcification in diabetics with and without chronic kidney disease. Kidney Int. 2005;68(3):1258-1266.
30. Yokoyama H, Aoki T, Imahori M, Kuramitsu M. Subclinical atherosclerosis is increased in type 2 diabetic patients with microalbuminuria evaluated by intima-media thickness and pulse wave velocity. Kidney Int. 2004;66(1):448-454.
31. Baykan M, Erdogan T, Erem C, et al. The relationship between flow-mediated dilatation and left ventricular function in type 2 diabetic patients with microalbuminuria. Endocrine. 2006;30(2):197-202.
32. Malik AR, Sultan S, Turner ST, Kullo IJ. Urinary albumin excretion is associated with impaired flow- and nitroglycerin-mediated brachial artery dilatation in hypertensive adults. J Hum Hypertens. 2007 Mar;21(3):231-238. Epub 2007 Jan 18.
33. Kohara K, Tabara Y, Tachibana R, Nakura J, Miki T. Microalbuminuria and arterial stiffness in a general population: the Shimanami Health Promoting Program (J-SHIPP) study. Hypertens Res. 2004;27(7):471-477.
34. Stehouwer CD, Henry RM, Dekker JM, Nijpels G, Heine RJ, Bouter LM. Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction - the Hoorn Study. Kidney Int Suppl. 2004 Nov;92:S42-44.
35. Montagna G, Buzio C, Calderini C, Quaretti P, Migone L. Relationship of proteinuria and albuminuria to posture and to urine collection period. Nephron. 1983;35(2):143-144.
36. Koopman MG, Krediet RT, Koomen GC, Strackee J, Arisz L. Circadian rhythm of proteinuria: consequences of the use of urinary protein:creatinine ratios. Nephrol Dial Transplant. 1989;4(1):9-14.
37. Hansen JM, Olsen NV, Feldt-Rasmussen B, et al. Albuminuria and overall capillary permeability of albumin in acute altitude hypoxia. J Appl Physiol. 1994;76(5):1922-1927.
38. Lewis DM, Bradwell AR, Shore AC, Beaman M, Tooke JE. Capillary filtration coefficient and urinary albumin leak at altitude. Eur J Clin Invest. 1997;27(1):64-68.
39. Berton G, Cordiano R, Palmieri R, Cucchini F, De Toni R, Palatini P. Microalbuminuria during acute myocardial infarction: a strong predictor for 1-year mortality. Eur Heart J. 2001;22(16):1466-1475.
40. Pflueger AC, Schenk F, Osswald H. Increased sensitivity of the renal vasculature to adenosine in streptozotocin-induced diabetes mellitus rats. Am J Physiol. 1995;269(4, pt 2):F529-F535.
41. Pflueger AC, Larson TS, Hagl S, Knox FG. Role of nitric oxide in intrarenal hemodynamics in experimental diabetes mellitus in rats. Am J Physiol. 1999;277(3, pt 2):R725-R733.
42. Knight SF, Quigley JE, Yuan J, Roy SS, Elmarakby A, Imig JD. Endothelial dysfunction and the development of renal injury in spontaneously hypertensive rats fed a high-fat diet. Hypertension. 2008 Feb;51(2):352-359. Epub 2007 Dec 24.
43. Solomon SD, Lin J, Solomon CG, et al, Prevention of Events With ACE Inhibition (PEACE) Investigators. Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease. Circulation. 2007 Dec 4;116(23):2687-2693. Epub 2007 Nov 19.
44. Moinuddin I, Leehey DJ. A comparison of aerobic exercise and resistance training in patients with and without chronic kidney disease. Adv Chronic Kidney Dis. 2008;15(1):83-96.
45. Geluk CA, Asselbergs FW, Hillege HL, et al. Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial. Eur Heart J. 2005 Jul;26(13):1314-1320. Epub 2005 Apr 8.
46. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care. 2005;28(11):2728-2732.
47. Agarwal R. Effects of statins on renal function [published correction appears in Mayo Clin Proc. 2007;82(12):1579]. Mayo Clin Proc. 2007;82(11):1381-1390.
48. Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005;68(6):2823-2828.
49. Imano E, Kanda T, Nakatani Y, et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care. 1998;21(12):2135-2139.
50. Ruggenenti P, Gaspari F, Perna A, Remuzzi G. Cross sectional longitudinal study of spot morning urine protein: creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes [published correction appears in BMJ. 31(7171):1491]. BMJ. 1998;316(7130):504-509.
51. Mattix HJ, Hsu CY, Shaykevich S, Curhan G. Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race. J Am Soc Nephrol. 2002;13(4):1034-1039.
52. Mogensen CE, Vestbo E, Poulsen PL, et al. Microalbuminuria and potential confounders: a review and some observations on variability of urinary albumin excretion. Diabetes Care. 1995;18(4):572-581.
53. Derhaschnig U, Kittler H, Woisetschläger C, Bur A, Herkner H, Hirschl MM. Microalbumin measurement alone or calculation of the albumin/creatinine ratio for the screening of hypertension patients? Nephrol Dial Transplant. 2002;17(1):81-85.
54. Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Am J Kidney Dis. 2003;42(4):617-622.
55. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet. 1982;1(8287):1430-1432.
56. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310(6):356-360.
57. Rossing P, Hommel E, Smidt UM, Parving HH. Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes. 1993;42(5):715-719.
58. Jacobsen P, Rossing K, Tarnow L, et al. Progression of diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int Suppl. 1999 Jul; 71:S101-S105.
59. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. Progression of diabetic nephropathy. Kidney Int. 2001;59(2):702-709.
60. Rossing P, Hougaard P, Parving HH. Progression of microalbuminuria in type 1 diabetes: ten-year prospective observational study. Kidney Int. 2005;68(4):1446-1450.
61. Kent DM, Jafar TH, Hayward RA, et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol. 2007 Jun;18(6):1959-1965. Epub 2007 May 2.
62. Jafar TH, Stark PC, Schmid CH, et al; AIPRD Study Group. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int. 2001;60(3):1131-1140.
63. Jafar TH, Stark PC, Schmid CH, et al; AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139(4):244-252.
64. Hillege HL, Fidler V, Diercks GF, et al; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106(14):1777-1782.
65. Ferris M, Hogan SL, Chin H, et al. Obesity, albuminuria, and urinalysis findings in US young adults from the Add Health Wave III study. Clin J Am Soc Nephrol. 2007 Nov;2(6):1207-1214. Epub 2007 Oct 17.
66. Lieb W, Mayer B, Stritzke J, et al. Association of low-grade urinary albumin excretion with left ventricular hypertrophy in the general population: the MONICA/KORA Augsburg Echocardiographic Substudy. Nephrol Dial Transplant. 2006 Oct;21(10):2780-2787. Epub 2006 Jul 31.
67. Arnlöv J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation. 2005 Aug 16;112(7):969-975. Epub 2005 Aug 8.
68. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med. 1997;157(13):1413-1418.
69. Jager A, Kostense PJ, Ruhé HG, et al. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol. 1999;19(3):617-624.
70. Hoy WE, Wang Z, VanBuynder P, Baker PR, Mathews JD. The natural history of renal disease in Australian Aborigines, part 1: changes in albuminuria and glomerular filtration rate over time. Kidney Int. 2001;60(1):243-248.
71. Rachmani R, Levi Z, Lidar M, Slavachevski I, Half-Onn E, Ravid M. Considerations about the threshold value of microalbuminuria in patients with diabetes mellitus: lessons from an 8-year follow-up study of 599 patients. Diabetes Res Clin Pract. 2000;49(2-3):187-194.
72. Gerstein HC, Mann JF, Yi Q, et al; HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421-426.
73. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation. 2004 Jul 6;110(1):32-35. Epub 2004 Jun 21.
74. Romundstad S, Holmen J, Hallan H, Kvenild K, Ellekjaer H. Microalbuminuria and all-cause mortality in treated hypertensive individuals: does sex matter? the Nord-Trøndelag Health Study (HUNT), Norway. Circulation. 2003 Dec 2;108(22):2783-2789. Epub 2003 Nov 17.
75. Yuyun MF, Khaw KT, Luben R, et al. Microalbuminuria, cardiovascular risk factors and cardiovascular morbidity in a British population: the EPIC-Norfolk population-based study. Eur J Cardiovasc Prev Rehabil. 2004;11(3):207-213.
76. Romundstad S, Holmen J, Kvenild K, Hallan H, Ellekjaer H. Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study: the Nord-Trøndelag Health Study (HUNT), Norway. Am J Kidney Dis. 2003;42(3):466-473.
77. Palatini P, Graniero GR, Canali C, et al. Relationship between albumin excretion rate, ambulatory blood pressure and left ventricular hypertrophy in mild hypertension. J Hypertens. 1995;13(12, pt 2):1796-1800.
78. Peterson GE, de Backer T, Gabriel A, et al; African American Study of Kidney Disease Investigators. Prevalence and correlates of left ventricular hypertrophy in the African American Study of Kidney Disease Cohort Study. Hypertension. 2007 Dec;50(6):1033-1039. Epub 2007 Oct 29.
79. Furtner M, Kiechl S, Mair A, et al. Urinary albumin excretion is independently associated with carotid and femoral artery atherosclerosis in the general population. Eur Heart J. 2005 Feb;26(3):279-287. Epub 2004 Nov 30.
80. Wang TJ, Evans JC, Meigs JB, et al. Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation. 2005 Mar 22;111(11):1370-1376. Epub 2005 Feb 28.
81. Palatini P, Mormino P, Mos L, et al; HARVEST Study Group. Microalbuminuria, renal function and development of sustained hypertension: a longitudinal study in the early stage of hypertension. J Hypertens. 2005;23(1):175-182.
82. Ingelsson E, Sundström J, Lind L, et al. Low-grade albuminuria and the incidence of heart failure in a community-based cohort of elderly men. Eur Heart J. 2007 Jul;28(14):1739-1745. Epub 2007 May 11.
83. Jørgensen L, Jenssen T, Johnsen SH, et al. Albuminuria as risk factor for initiation and progression of carotid atherosclerosis in non-diabetic persons: the Tromsø Study. Eur Heart J. 2007 Feb;28(3):363-369. Epub 2006 Nov 28.
84. Bakker SJ, Gansevoort RT, Stuveling EM, Gans RO, de Zeeuw D. Microalbuminuria and C-reactive protein: similar messengers of cardiovascular risk? Curr Hypertens Rep. 2005;7(5):379-384.
85. Stuveling EM, Bakker SJ, Hillege HL, et al; PREVEND Study Group. C-reactive protein modifies the relationship between blood pressure and microalbuminuria. Hypertension. 2004 Apr;43(4):791-796. Epub 2004 Feb 16.
86. Hallan S, Astor B, Romundstad S, Aasarød K, Kvenild K, Coresh J. Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals: the HUNT II Study. Arch Intern Med. 2007;167(22):2490-2496.
87. Stam F, van Guldener C, Becker A, et al. Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study. J Am Soc Nephrol. 2006 Feb;17(2):537-545. Epub 2005 Dec 28.
88. Rodondi N, Yerly P, Gabriel A, et al. Microalbuminuria, but not cystatin C, is associated with carotid atherosclerosis in middle-aged adults. Nephrol Dial Transplant. 2007 Apr;22(4):1107-1114. Epub 2007 Jan 5.
89. Asselbergs FW, Diercks GF, Hillege HL, et al; Prevention of Renal and Vascular endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004 Nov 2;110(18):2809-2816. Epub 2004 Oct 18.
90. Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan Intervention For Endpoint reduction in hypertension study. Hypertension. 2005 Feb;45(2):198-202. Epub 2005 Jan 17.
91. Lechner BL, Bockenhauer D, Iragorri S, Kennedy TL, Siegel NJ. The risk of cardiovascular disease in adults who have had childhood nephrotic syndrome. Pediatr Nephrol. 2004 Jul;19(7):744-748. Epub 2004 Apr 15.
92. Axel DI, Riessen R, Runge H, Viebahn R, Karsch KR. Effects of cerivastatin on human arterial smooth muscle cell proliferation and migration in transfilter cocultures. J Cardiovasc Pharmacol. 2000;35(4):619-629.
93. Son BK, Kozaki K, Iijima K, et al. Gas6/Axl-PI3K/Akt pathway plays a central role in the effect of statins on inorganic phosphate-induced calcification of vascular smooth muscle cells. Eur J Pharmacol. 2007 Feb 5;556(1-3):1-8. Epub 2006 Oct 18.
94. Whittaker A, Moore JS, Vasa-Nicotera M, Stevens S, Samani NJ. Evidence for genetic regulation of endothelial progenitor cells and their role as biological markers of atherosclerotic susceptibility. Eur Heart J. 2008 Feb;29(3):332-338. Epub 2008 Jan 12.